Cargando…

2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies

The oncometabolite 2-hydroxyglutarate (2-HG) plays a key role in differentiation blockade and metabolic reprogramming of cancer cells. Approximatively 20–30% of acute myeloid leukemia (AML) cases carry mutations in the isocitrate dehydrogenase (IDH) enzymes, leading to a reduction in the Krebs cycle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raimondi, Vittoria, Ciotti, Giulia, Gottardi, Michele, Ciccarese, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220225/ https://www.ncbi.nlm.nih.gov/pubmed/35740380 http://dx.doi.org/10.3390/biomedicines10061359

Ejemplares similares

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing
por: Sperotto, Alessandra, et al.
Publicado: (2023)

Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
por: Mosna, Federico, et al.
Publicado: (2016)

Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict IDH mutation in acute myeloid leukemia
por: Zhang, Chelsea, et al.
Publicado: (2023)

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
por: Ciotti, Giulia, et al.
Publicado: (2022)

The transformative journey of chronic myeloid leukemia
por: Neelakantan, Pratap, et al.
Publicado: (2018)

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
por: Chen, Jing-Yi, et al.
Publicado: (2016)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
por: Mosna, Federico, et al.
Publicado: (2017)

The Roles of 2-Hydroxyglutarate
por: Du, Xin, et al.
Publicado: (2021)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

2-Hydroxyglutarate in Cancer Cells
por: Ježek, Petr
Publicado: (2020)

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
por: Gross, Stefan, et al.
Publicado: (2010)

Oncogenic pathways and the electron transport chain: a dangeROS liaison
por: Raimondi, Vittoria, et al.
Publicado: (2019)

Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
por: Peled, Amnon, et al.
Publicado: (2013)

Progress in understanding 2-hydroxyglutaric acidurias
por: Kranendijk, Martijn, et al.
Publicado: (2012)

The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
por: Reiter-Brennan, Cara, et al.
Publicado: (2018)

D-2-Hydroxyglutarate in Glioma Biology
por: Chou, Fu-Ju, et al.
Publicado: (2021)

Pityriasis rosea during COVID-19 and its pathogenesis
por: Drago, Francesco, et al.
Publicado: (2022)

D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells
por: Ugele, Ines, et al.
Publicado: (2019)

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis
por: Demir, Derya
Publicado: (2023)

The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons
por: Brauburger, Katja, et al.
Publicado: (2011)

Metabolism, Activity, and Targeting of D-and L-2-Hydroxyglutarates
por: Ye, Dan, et al.
Publicado: (2018)

D-2-Hydroxyglutaric Aciduria with Enchondromatosis and Angiokeratoma Circumscriptum
por: Preston, Allie, et al.
Publicado: (2019)

Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney
por: Brinkley, Garrett, et al.
Publicado: (2020)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017)

Therapies for acute myeloid leukemia: vosaroxin
por: Sayar, Hamid, et al.
Publicado: (2017)

Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
por: Velthaus, Arne, et al.
Publicado: (2019)

The characteristics of circRNA as competing endogenous RNA in pathogenesis of acute myeloid leukemia
por: Zhang, Siyuan
Publicado: (2021)

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017)

An interesting case of metabolic dystonia: L-2 hydroxyglutaric aciduria
por: Balaji, Padma, et al.
Publicado: (2014)

Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
por: Gelman, Susan J., et al.
Publicado: (2015)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

Writer’s cramp as a presentation of L-2-hydroxyglutaric aciduria
por: Termsarasab, Pichet, et al.
Publicado: (2014)

The immunometabolite S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate
por: Tyrakis, Petros A., et al.
Publicado: (2016)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d10vtbvpiv78bsa1k0m5ug9cb8